梅斯健康(02415.HK)2024年度純利跌54.6%至2496.7萬元
格隆匯3月29日丨梅斯健康(02415.HK)公佈年度業績,截至2024年12月31日止年度,公司收益爲人民幣2.61億元,同比減少25.4%;母公司擁有人應佔溢利爲人民幣2496.7萬元,同比減少54.6%,每股基本及攤薄盈利分別約爲人民幣0.05元及人民幣0.05元。
截至2024年12月31日,集團累計向12家中國頂級研究型醫院提供醫療解決方案,並已覆蓋超過2,000家醫院,覆蓋範圍從一線及二線城市,擴張到下沉的縣域和基層醫療機構。集團累計服務的藥械企業數量截至2024年12月31日達到613家
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.